Microfluidics Market Report 2025

The microfluidics market size has grown rapidly in recent years. It will grow from $9.16 billion in 2024 to $10.38 billion in 2025 at a compound annual growth rate (CAGR) of 13.3%. The growth in the historic period can be attributed to strong economic growth in emerging markets, increased incidences of chronic diseases, increased number of new infections and deaths due to COVID-19 disease, and increased healthcare expenditure.

The microfluidics market size is expected to see rapid growth in the next few years. It will grow to $18.25 billion in 2029 at a compound annual growth rate (CAGR) of 15.2%. The growth in the forecast period can be attributed to rising demand for point-of-care testing in the healthcare industry, increasing need for microfluidics, and an increased number of clinical studies for cell-based therapies. Major trends in the forecast period include the use of white blood cell isolation technology, product innovations, adoption of digital microfluidics platform, use of 3d printing in microfluidics, technological advancements, use of invitro diagnostics tests, and strategic partnerships and collaborations.

The growing demand for advanced point-of-care testing (POCT) in the healthcare sector is driving the microfluidics market. POCT enables healthcare providers to identify and diagnose illnesses quickly, often at or near the patient's location, significantly faster than traditional laboratory testing. Microfluidics-based POCT devices are portable, low-cost, and highly accurate. Countries worldwide are increasingly investing in POCT capabilities to offer convenient testing services to their populations, which is expected to enhance the demand for innovative microfluidics used in these devices. For example, in November 2023, Eurostat, the statistical office of the European Union, reported that in 2022, approximately 36.1% of the EU population aged 16 years or older indicated they had a long-standing illness or health problem. Therefore, the rising demand for point-of-care testing is anticipated to drive the growth of the microfluidics market during the forecast period.

The rise in clinical studies for cell-based therapies has significantly contributed to the growth of the microfluidics market during the historical period. Microfluidics has emerged as a promising platform for advancing biomanufacturing in drug, gene, and cell therapies by enabling enhanced synthesis of nanoscale drug and gene delivery systems, microencapsulation of drugs or cells, intracellular delivery of macromolecules, and the fabrication of macroscale constructs from micro-nano fibers. For example, in July 2023, the American Society of Gene and Cell Therapy, a US-based medical and scientific development organization, reported a 58% increase in non-oncology gene and cell therapy clinical trials in the second quarter of 2023 compared to the first quarter. Thus, the growing number of clinical studies focused on cell-based therapies is expected to drive the growth of the microfluidics market during the forecast period.

Innovation in product development is a significant contributor to the rapid growth of the microfluidics market. Companies in the microfluidics sector are actively creating innovative products to meet the escalating industry demand and enhance their market positions. For instance, Miroculus, Inc., a California-based developer of personal lab automation solutions, launched Micro Canvas in March 2022, a digital microfluidics platform designed to automate complex next-generation sequencing platforms.

Major companies in the microfluidics market are actively focused on developing innovative technological solutions to enhance their market positions. For example, in March 2024, Takara Bio, a Japan-based manufacturer of scientific reagents, launched the first commercial dissolvable microfluidic lentiviral transduction enhancer. This product employs a unique dissolvable microfluidic platform that enables precise control over the transduction process, thereby improving the delivery of lentiviral vectors into target cells. The enhancer is specifically designed to significantly boost the efficiency of lentiviral transduction, which is vital for gene therapy applications, ensuring more effective gene delivery into cells. Additionally, the microfluidic system simplifies the experimental setup, making it accessible for researchers without requiring extensive technical expertise.

In December 2022, CPS Fluidics, a US-based manufacturer of custom fluidics products, acquired Hexano Corp. for an undisclosed amount. This strategic acquisition is intended to strengthen CPS Fluidics' capabilities in the manufacturing and prototyping of microfluidic devices by leveraging Hexano's expertise and established client base. Hexano Corp. specializes in the production of microfluidic devices and is also based in the United States.

Major companies operating in the microfluidics market include Thermo Fisher Scientific, Agilent Technologies, Illumina Inc, Bio-Rad Laboratories, Fluidigm Corporation, Dolomite Microfluidics, PerkinElmer, Inc., Biosurfit SA, Sphere Fluidics Limited, Micronit Micro Technologies B.V., Parker Hannifin Corp., Fluigent, Camozzi, Gems Sensors, Inc., Aignep S.P.A., SMC Corporation, Cellix Ltd, Elveflow, Microliquid, S.L., Danaher Corporation, BD, Absolute Ozone, FlowJEM, uFluidix, QuantWave Technologies Inc., Shelron Enterprises, Harvard Bioscience, Inc., Abaxis, Inc., OPKO Health, Inc., IDEX Health & Science LLC, Stämm, The Advanced Microfluidics and Microdevices Laboratory, Chromatotec Group, Abbott, Safarmex PTY Ltd.

North America was the largest region in the microfluidics market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the microfluidics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the microfluidics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, and Canada.

Microfluidics is the science and technology of devices designed to process or manipulate small volumes of fluid (ranging from 10-9 to 10-18L) through channels with widths of a few tens to several hundred micrometers. Microfluidic devices are capable of performing chemical analysis on small amounts of liquid, such as droplets of blood. These devices have emerged as an alternative to conventional laboratory techniques, offering the potential to conduct complete laboratory protocols on a single small chip.

The primary types of microfluidics encompass silicone-based microfluidics, glass-based microfluidics, and polymer-based microfluidics. Silicon-based microfluidics involve the use of micro-manufactured devices for chip-scale management of tiny volumes of fluids. These devices are created by combining silicon with other materials such as glass, polymers, or other substances. Silicon-based microfluidics find applications in various fields, including industrial and environmental processes, drug delivery, pharmaceutical and life science research, analysis, and clinical and veterinary diagnostics.

The microfluidics market research report is one of a series of new reports that provides microfluidics market statistics, including microfluidics industry global market size, regional shares, competitors with a microfluidics market share, detailed microfluidics market segments, market trends and opportunities, and any further data you may need to thrive in the microfluidics industry. This microfluidics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The microfluidics market includes revenues earned by entities by developing molecular sensors based on bioassays, such as DNA amplification and analysis, cell separation, and immunoassay, among many more examples. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.